Hepatitis B virus infection

The Lancet

Volumn 373, Issue 9663, 2009, Pages 582-592

  Liaw, Yun Fan ^a   Chu, Chia Ming ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ENTECAVIR; HEPATITIS B VACCINE; INTERFERON; LAMIVUDINE; PEGINTERFERON ALPHA2A; TELBIVUDINE; TENOFOVIR;

ALLOGRAFT; ANOREXIA; ANTIVIRAL THERAPY; BONE MARROW SUPPRESSION; CHEMOTHERAPY; COUNSELING; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FLU LIKE SYNDROME; GENOTYPE; HAIR LOSS; HEALTH CARE COST; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; LIVER TRANSPLANTATION; MENTAL INSTABILITY; PATHOPHYSIOLOGY; PREVALENCE; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; RECURRENT DISEASE; REINFECTION; REVIEW; SIDE EFFECT; THYROID DISEASE; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VACCINATION; VIRUS REPLICATION; WEIGHT REDUCTION;

EID: 59749096640     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)60207-5     Document Type: Review

References (131)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepatol 11 (2004) 97-107
2. Summers J., and Mason W.S. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell 29 (1982) 403-415
3. Kao J.H. Role of viral factors in the natural course and therapy of chronic hepatitis B. Hepatol Int 1 (2007) 415-430
4. Wasley A., Grytdal S., and Gallagher K. Surveillance for acute viral hepatitis-United States, 2006. MMWR Morb Mortal Wkly Rep 57 (2008) 1-24
5. Okada K., Kamiyama I., Inomata M., Imai M., and Miyakawa Y. e antigen and anti-e in the serum of asymptomatic carrier mothers as indicators of positive and negative transmission of hepatitis B virus to their infants. N Engl J Med 294 (1976) 746-749
6. Botha J.F., Ritchie M.J., Dusheiko G.M., Mouton H.W., and Kew M.C. Hepatitis B virus carrier state in black children in Ovamboland: role of perinatal and horizontal infection. Lancet 323 (1984) 1210-1212
7. Lin H.H., Kao J.H., Chang T.C., Hsu H.Y., and Chen D.S. Secular trend of age-specific prevalence of hepatitis B surface and e antigenemia in pregnant women in Taiwan. J Med Virol 69 (2003) 466-470
8. Chu C.J., Keeffe E.B., Han S.H., et al. Prevalence of HBV precore/core promoter variants in the United States. Hepatology 38 (2003) 619-628
9. Manesis E.K. HBeAg-negative chronic hepatitis B: from obscurity to prominence. J Hepatol 45 (2006) 343-346
10. McKnight C.A., Des Jarlais D.C., Perlis T., and Eigo K. Syringe exchange programs-United States, 2005. MMWR Morb Mortal Wkly Rep 56 (2007) 1164-1167
11. WHO. Hepatitis B vaccines. Wkly Epidemiol Rec 79 (2004) 253-264
12. Zuckerman J., van Hattum J., Cafferkey M., et al. Should hepatitis B vaccination be introduced into childhood immunisation programmes in northern Europe?. Lancet Infect Dis 7 (2007) 410-419
13. Ni Y.H., Huang L.M., Chang M.H., et al. Two decades of universal hepatitis B vaccination in Taiwan: impact and implication for future strategies. Gastroenterology 132 (2007) 1287-1293
14. Chien Y.C., Jan C.F., Kuo H.S., and Chen C.J. Nationwide hepatitis B vaccination program in Taiwan: effectiveness in the 20 years after it was launched. Epidemiol Rev 28 (2006) 126-135
15. Murray J.M., Wieland S.F., Purcell R.H., and Chisari F.V. Dynamics of hepatitis B virus clearance in chimpanzees. Proc Natl Acad Sci USA 102 (2005) 17780-17785
16. Guidotti L.G., Rochford R., Chung J., Shapiro M., Purcell R., and Chisari F.V. Viral clearance without destruction of infected cells during acute HBV infection. Science 284 (1999) 825-829
17. Bertoletti A., Maini M., and Williams R. Role of hepatitis B virus specific cytotoxic T cells in liver damage and viral control. Antiviral Res 60 (2003) 61-66
18. Thimme R., Wieland S., Steiger C., et al. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 77 (2003) 68-76
19. Visvanathan K., and Lewin S.R. Immunopathogenesis: role of innate and adaptive immune responses. Semin Liver Dis 26 (2006) 104-115
20. Rehermann B. Chronic infections with hepatotropic viruses: mechanisms of impairment of cellular immune responses. Semin Liver Dis 27 (2007) 152-160
21. Maini M.K., Boni C., Lee C.K., et al. The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 191 (2000) 1269-1280
22. McMahon B.J., Alward W.L., Hall D.B., et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis 151 (1985) 599-603
23. In: Liaw Y.F. (Ed). Asia-Pacific Pocket Guide to Hepatitis B (2006), University of Wisconsin Board of Regents and MDG Development Group, New Jersey
24. Chu C.M., and Liaw Y.F. Increased incidence of fulminant hepatic failure in previously unrecognized HBsAg carriers with acute hepatitis independent of etiology. Infection 33 (2005) 136-139
25. Lok A.S., and McMahon B.J. Chronic hepatitis B. Hepatology 45 (2007) 507-539
26. Hadziyannis S.J. Unrevealing the natural course of the so-called "inactive HBsAg or HBV carrier state". Hepatol Int 1 (2007) 218-284
27. Gish R.G., and Locarnini S.A. Chronic hepatitis B: current testing strategies. Clin Gastroenterol Hepatol 4 (2006) 666-676
28. Chen H.L., and Chang C.J. Pediatric fulminant hepatic failure in endemic areas of hepatitis B infection: 15 years after universal hepatitis B vaccination. Hepatology 39 (2004) 58-63
29. Friedt M., Gerner P., Lausch E., Trübel H., Zabel B., and Wirth S. Mutations in the basic core promotor and the precore region of hepatitis B virus and their selection in children with fulminant and chronic hepatitis B. Hepatology 29 (1999) 1252-1258
30. Rehermann B., Ferrari C., Pasquinelli C., and Chisari F.V. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T lymphocyte response. Nat Med 2 (1996) 1104-1108
31. Raimondo G., Pollicino T., Cacciola I., and Squadrito G. Occult hepatitis B virus infection. J Hepatol 46 (2007) 160-170
32. Milich D., and Liang T.J. Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection. Hepatology 38 (2003) 1075-1086
33. Chu C.M., Karayiannis P., Fowler M.J.F., Maujardino J., Liaw Y.F., and Thomas H.C. Natural history of chronic hepatitis B virus infection in Taiwan: studies of hepatitis B virus DNA in serum. Hepatology 5 (1985) 431-434
34. Hsu Y.S., Chien R.N., Yeh C.T., et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 35 (2002) 1522-1527
35. Fattovich G., Olivari N., Pasino M., D'Onofrio M., Martone E., and Donato F. Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years. Gut 57 (2008) 84-90
36. Liaw Y.F., Leung N., Kao J.H., et al. Asian-Pacific Consensus statement on the management of chronic hepatitis B: 2008 update. Hepatol Int 2 (2008) 263-283
37. Lai C.L., Ratziu V., Yuen M.F., and Poynard T. Viral hepatitis B. Lancet 362 (2003) 2089-2094
38. Hui C.K., Leung N., Yuen S.T., et al. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase. Hepatology 46 (2007) 395-401
39. Boni C., Bertoletti A., Penna A., et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 102 (1998) 968-975
40. Chu C.M., Yeh C.T., Sheen I.S., and Liaw Y.F. Subcellular localization of hepatitis B core antigen in relation to hepatocyte regeneration in chronic hepatitis B. Gastroenterology 109 (1995) 1926-1932
41. Chu C.M., Yeh C.T., Lee C.S., Sheen I.S., and Liaw Y.F. Precore stop mutant in HBeAg-positive patients with chronic hepatitis B: clinical characteristics and correlation with the course of HBeAg-to-anti-HBe seroconversion. J Clin Microbiol 40 (2002) 16-21
42. Yuen M.F., Sablon E., Yuan H.J., et al. Relationship between the development of precore and core promoter mutations and hepatitis B e antigen seroconversion in patients with chronic hepatitis B virus. J Infect Dis 186 (2002) 1335-1338
43. Liaw Y.F. Hepatitis flares and hepatitis B e antigen seroconversion: implication in anti-hepatitis B virus therapy. J Gastroenterol Hepatol 18 (2003) 246-252
44. Yuen M.F., Sablon E., Hui C.K., et al. Prognostic factors in severe exacerbation of chronic hepatitis B. Clin Infect Dis 36 (2003) 979-984
45. Chu C.M., Hung S.J., Lin J., Tai D.I., and Liaw Y.F. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med 116 (2004) 829-834
46. Yuen M.F., Yuan H.J., Wong D.K., et al. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut 54 (2005) 1610-1614
47. Chu C.M., and Liaw Y.F. Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B: a longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels at baseline. J Hepatol 43 (2005) 411-417
48. Chu C.M., and Liaw Y.F. Chronic hepatitis B virus infection acquired in childhood: special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion. J Viral Hepatol 14 (2007) 147-152
49. Chu C.J., Hussain M., and Lok A.S. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology 122 (2002) 1756-1762
50. Ni Y.H., Chang M.H., Wang K.J., et al. Clinical relevance of hepatitis B virus genotype in children with chronic infection and hepatocellular carcinoma. Gastroenterology 127 (2004) 1733-1738
51. Yuen M.F., Sablon E., Tanaka Y., et al. Epidemiological study of hepatitis B virus genotypes, core promoter and precore mutations of chronic hepatitis B infection in Hong Kong. J Hepatol 41 (2004) 119-125
52. Livingston S.E., Simonetti J.P., Bulkow L.R., et al. Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F. Gastroenterology 133 (2007) 1452-1457
53. Manno M., Cammà C., Schepis F., et al. Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years. Gastroenterology 127 (2004) 756-763
54. Zacharakis G.H., Koskinas J., Kotsiou S., et al. Natural history of chronic HBV infection: a cohort study with up to 12 years follow-up in North Greece (part of the Interreg I-II/EC-project). J Med Virol 77 (2005) 173-179
55. Bortolotti F., Guido M., Bartolacci S., et al. Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study. Hepatology 43 (2006) 556-562
56. Ni Y.H., Chang M.H., Chen P.J., et al. Viremia profiles in children with chronic hepatitis B virus infection and spontaneous e antigen seroconversion. Gastroenterology 132 (2007) 2340-2345
57. McMahon B.J., Holck P., Bulkow L., and Snowball M. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med 135 (2001) 759-768
58. Chu C.M., and Liaw Y.F. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology 45 (2007) 1187-1192
59. Sánchez-Tapias J.M., Costa J., Mas A., Bruguera M., and Rodés J. Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology 123 (2002) 1848-1856
60. Yuen M.F., Wong D.K., Sablon E., et al. HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects. Hepatology 39 (2004) 1694-1701
61. Chen Y.C., Sheen I.S., Chu C.M., and Liaw Y.F. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology 123 (2002) 1084-1089
62. Arase Y., Ikeda K., Suzuki F., et al. Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B. Am J Med 119 71 (2006) e9-e16
63. Bonino F., and Brunetto M.R. Chronic hepatitis B e antigen (HBeAg) negative, anti-HBe positive hepatitis B: an overview. J Hepatol 39 suppl (2003) 160-163
64. Chu C.M., and Liaw Y.F. Spontaneous relapse of hepatitis in inactive HBsAg carriers. Hepatol Int 1 (2007) 311-315
65. Chu C.M., and Liaw Y.F. Predictive factors for reactivation of hepatitis B following hepatitis B e antigen seroconversion in chronic hepatitis B. Gastroenterology 133 (2007) 1458-1465
66. Feld J.J., Ayers M., El-Ashry D., Mazzulli T., Tellier R., and Heathcote E.J. Hepatitis B virus DNA prediction rules for hepatitis B e antigen-negative chronic hepatitis B. Hepatology 46 (2007) 1057-1070
67. Iloeje U.H., Yang H.I., Su J., Jen C.L., You S.L., and Chen C.J. The Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-In HBV (the REVEAL-HBV) Study Group Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130 (2006) 678-686
68. Chen C.J., Yang H.I., Su J., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295 (2006) 65-73
69. Iloeje U.H., Yang H.I., Jen C.L., et al. Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-hepatitis B Virus Study Group. Risk and predictors of mortality associated with chronic hepatitis B infection. Clin Gastroenterol Hepatol 5 (2007) 921-931
70. Liaw Y.F. Hepatitis B virus replication and liver disease progression: the impact of antiviral therapy. Antivir Ther 11 (2006) 669-679
71. Liaw Y.F., Tai D.I., Chu C.M., and Chen T.J. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 8 (1988) 493-496
72. Yang H.I., Lu S.N., Liaw Y.F., et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 347 (2002) 168-174
73. Kao J.H., Chen P.J., Lai M.Y., and Chen D.S. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 118 (2000) 554-559
74. Sumi H., Yokosuka O., Seki N., et al. Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. Hepatology 37 (2003) 19-26
75. Yuen M.F., Sablon E., Yuan H.J., et al. Significance of hepatitis B genotype in acute exacerbation, HBeAg seroconversion, cirrhosis-related complications, and hepatocellular carcinoma. Hepatology 37 (2003) 562-567
76. Duong T.N., Horiike N., Michitaka K., et al. Comparison of genotypes C and D of the hepatitis B virus in Japan: a clinical and molecular biological study. J Med Virol 72 (2004) 551-557
77. Lin S.M., Yu M.L., Lee C.M., et al. Interferon therapy in HBeAg positive chronic hepatitis reduces cirrhosis and hepatocellular carcinoma. J Hepatol 46 (2007) 45-52
78. Brunetto M.R., Oliveri F., Coco B., et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 36 (2002) 263-270
79. Park B.K., Park Y.N., Ahn S.H., et al. Long-term outcome of chronic hepatitis B based on histological grade and stage. J Gastroenterol Hepatol 22 (2007) 383-388
80. Liaw Y.F., Chen Y.C., Sheen I.S., et al. Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. Gastroenterology 126 (2004) 1024-1029
81. Chu C.M., and Liaw Y.F. Hepatitis B virus-related cirrhosis: natural history and treatment. Semin Liver Dis 26 (2006) 142-152
82. Chen Y.C., Chu C.M., Yeh C.T., and Liaw Y.F. Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study. Hepatol Int 1 (2007) 267-273
83. Fattovich G., Pantalena M., Zagni I., Realdi G., Schalm S.W., Christensen E., and European Concerted Action on Viral Hepatitis (EUROHEP). Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol 97 (2002) 2886-2895
84. Yu M.W., Chang H.C., Liaw Y.F., et al. Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives. J Natl Cancer Inst 92 (2000) 1159-1164
85. Kao J.H., Chen P.J., Lai M.Y., and Chen D.S. Core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology 124 (2003) 327-334
86. Chan H.L., Hui A.Y., Wong M.L., et al. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut 53 (2004) 1494-1498
87. Yu M.W., Yeh S.H., Chen P.J., et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 97 (2005) 265-272
88. Chen C.H., Hung C.H., Lee C.M., et al. Pre-S deletion and complex mutations of hepatitis B virus related to advanced liver disease in HBeAg-negative patients. Gastroenterology 133 (2007) 1466-1474
89. Chou Y.C., Yu M.W., Wu C.F., et al. Temporal relationship between hepatitis B virus enhancer II/basal core promoter sequence variation and risk of hepatocellular carcinoma. Gut 57 (2008) 91-97
90. Liaw Y.F., and Sollano J.D. Factors influencing liver disease progression in chronic hepatitis B. Liver Int 26 suppl 2 (2006) 23-29
91. Ong S.C., Mak B., Aung M.O., Li S.C., and Lim S.G. Health-related quality of life in chronic hepatitis B patients. Hepatology 47 (2008) 1108-1117
92. Lai M., Hyatt B.J., Nasser I., Curry M., and Afdhal N.H. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol 47 (2007) 760-767
93. Marcellin P., Heathcote J., Gane E., et al. Tenofovir disoproxil fumarate (TDF) demonstrated superior antiviral efficacy to adefovir dipivoxil in two pivotal, randomized, double-blind, studies for the treatment of HBeAg-negative and HBeAg-positive chronic hepatitis B (CHB): study 102 and study 103. Hepatol Int 2 (2008) A139
94. Craxì A., Di Bona D., and Cammà C. Interferon-alpha for HBeAg-positive chronic hepatitis B. J Hepatol 39 suppl 1 (2003) 99-105
95. Cooksley W.G.F., Piratvisuth T., Lee S.D., et al. Peginterferon alpha 2a(40kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 10 (2003) 298-305
96. Lau G.K., Piratvisuth T., Luo K.X., et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 352 (2005) 2682-2695
97. Janssen H., van Zonneveld M., Senturk H., et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365 (2005) 123-129
98. Niederau C., Heintges T., Lange S., et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 334 (1996) 1422-1427
99. van Zonneveld M., Honkoop P., Hansen B.E., et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 39 (2004) 804-810
100. Papatheodoridis G.V., Dimou E., Dimakopoulos K., et al. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology 42 (2005) 121-129
101. Marcellin P., Lau G.K.K., Bonino F., et al. Peginterferon alfa-2a alone, lamivudine alone and the two in combination in patients with HBeAg negative chronic hepatitis B. N Engl J Med 35 (2004) 1206-1217
102. Bonino F., Marcellin P., Lau G.K., et al. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 56 (2007) 699-705
103. Piratvisuth T., Lau G., Chao Y.C., et al. Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B. Hepatol Int 2 (2008) 102-110
104. Fried M.W., Piratvisuth T., Lau G.K., et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 47 (2008) 428-434
105. Marcellin P., Piratvisuth T., Brunetto M., et al. Virological and biochemical response in patients with HBeAg-negative chronic hepatitis B treated with Pegasys with or without lamivudine: results of 4-year follow-up. Hepatol Int 2 (2008) A114
106. Marcellin P., Chang T.T., Lim S.G., et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 348 (2003) 808-816
107. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 131 (2006) 1743-1751
108. Lai C.L., Shouval D., Lok A.S., et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 354 (2006) 1011-1020
109. Gish R.G., Lok A.S., Chang T.T., et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 133 (2007) 1437-1444
110. Lai C.L., Gane E., Liaw Y.F., et al. A comparison of telbivudine and lamivudine in patients with chronic hepatitis B. N Engl J Med 357 (2007) 34-46
111. Chien R.N., Liaw Y.F., Atkins M., and for Asian hepatitis Lamivudine Trial Group. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Hepatology 30 (1999) 770-774
112. Perrillo R.P., Lai C.L., Liaw Y.F., et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 36 (2002) 186-194
113. Chien R.N., Lin C.H., and Liaw Y.F. The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B. J Hepatol 38 (2003) 322-327
114. Fontana R.J., Hann H.W., Perrillo R.P., et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 123 (2002) 719-727
115. Hann H.W., Fontana R.J., Wright T., et al. A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis. Liver Transpl 9 (2003) 49-56
116. Tassopoulos N.C., Volpes R., Pastore G., et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 29 (1999) 889-896
117. Chien R.N., and Liaw Y.F. Short term lamivudine therapy in active HBeAg-negative chronic hepatitis B patients in Taiwan. Antivir Ther 11 (2006) 947-952
118. Liaw Y.F., Sung J., Chow W.C., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351 (2004) 1521-1531
119. Lok A.S., Zoulim F., Locarnini S., et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 46 (2007) 254-265
120. Liaw Y.F., Chien R.N., Yeh C.T., Tsai S.L., and Chu C.M. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 30 (1999) 567-572
121. Dienstag J.L., Goldin R.D., Heathcote E.J., et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 124 (2003) 105-117
122. Di Marco V., Marzano A., Lampertico P., et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 40 (2004) 883-891
123. Rapti I., Dimou E., Mitsoula P., and Hadziyannis S.J. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 45 (2007) 307-313
124. Lampertico P., Viganò M., Manenti E., et al. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 133 (2007) 1445-1451
125. Zoulim F., and Perrillo R. Hepatitis B: reflections on the current approach to antiviral therapy. J Hepatol 48 suppl (2008) 2-19
126. Flink H.J., Hansen B.E., Heathcote E.J., et al. Successful treatment with peginterferon alfa-2b of HBeAg-positive HBV non-responders to standard interferon or lamivudine. Am J Gastroenterol 101 (2006) 2523-2529
127. Lau G., Marcellin P., and Peters M. Chronic hepatitis B: a global health problem requiring coherent worldwide treatment strategies. Hepatol Int 1 (2007) 316-325
128. Lai C.L., Leung N., Teo E.K., et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 129 (2005) 528-536
129. Sung J.J., Lai J.Y., Zeuzem S., et al. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol 48 (2008) 728-735
130. Hoofnagle J.H., Doo E., Liang T.J., Fleischer R., and Lok A.S. Management of hepatitis B: summary of a clinical research workshop. Hepatology 45 (2007) 1056-1075
131. Lau G.K.K. Hepatitis B reactivation after chemotherapy: two decades of clinical research. Hepatol Int 2 (2008) 152-162